Erythropoietin prevents reactive oxygen species generation and renal tubular cell apoptosis at high glucose level

Biomedicine and Pharmacotherapy

Volumn 64, Issue 10, 2010, Pages 681-685

  Dang, J ^a   Jia, R ^a   Tu, Y ^a   Xiao, S ^a   Ding, G ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Apoptosis; Erythropoietin; High glucose; Reactive oxygen species; Renal tubule

Indexed keywords

CASPASE 3; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; GLUCOSE; PROTEIN BAX; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; APOPTOSIS; ARTICLE; DRUG EFFECT; FLOW CYTOMETRY; KIDNEY TUBULE CELL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CELL LINE; ERYTHROPOIETIN; FLOW CYTOMETRY; GLUCOSE; KIDNEY TUBULAR NECROSIS, ACUTE; KIDNEY TUBULES; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; REACTIVE OXYGEN SPECIES; RECEPTORS, ERYTHROPOIETIN; RNA, MESSENGER;

EID: 78649814383     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2010.06.011     Document Type: Article

References (28)

1. Rosen P., Nawroth P.P., King G., Moller W., Tritschler H.J., Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev 2001, 17:189-212.
2. The Diabetes Control Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986.
3. Prospective Diabetes Study (UKPDS) U.K Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
4. Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study group. N Engl J Med 1993, 329:1456-1462.
5. Lee E.A., Seo J.Y., Jiang Z., Yu M.R., Kwon M.K., Ha H., et al. Reactive oxygen species mediate high glucose-induced plasminogen activator inhibitor-1 up-regulation in mesangial cells and in diabetic kidney. Kidney Int 2005, 67:1762-1771.
6. Westenfelder C., Biddle D.L., Baranowski R.L. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int 1999, 55:808-820.
7. Bahlmann F.H., de Groot K., Haller H., Fliser D. Erythropoietin: is it more than correcting anaemia?. Nephrol Dial Transplant 2004, 19:20-22.
8. Toba H., Sawai N., Morishita M., Murata S., Yoshida M., Nakashima K., et al. Chronic treatment with recombinant human erythropoietin exerts renoprotective effects beyond hematopoiesis in streptozotocin-induced diabetic rat. Eur J Pharmacol 2009, 612:106-114.
9. Johnson D.W., Pat B., Vesey D.A., Guan Z., Endre Z., Gobe G.C. Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int 2006, 69:1806-1813.
10. Krantz S.B. Erythropoietin. Blood 1991, 77:419-434.
11. Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol Rev 1992, 72:449-489.
12. Bianchi R., Buyukakilli B., Brines M., Savino C., Cavaletti G., Oggioni N., et al. Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci U S A 2004, 101:823-828.
13. Bahlmann F.H., Song R., Boehm S.M., Mengel M., von Wasielewski R., Lindschau C., et al. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 2004, 110:1006-1012.
14. Koury S.T., Bondurant M.C., Koury M.J. Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization. Blood 1988, 71:524-527.
15. Maxwell P.H., Osmond M.K., Pugh C.W., Heryet A., Nicholls L.G., Tan C.C., et al. Identification of the renal erythropoietin-producing cells using transgenic mice. Kidney Int 1993, 44:1149-1162.
16. Bao Y., Jia R.H., Yuan J., Li J. Rosiglitazone ameliorates diabetic nephropathy by inhibiting reactive oxygen species and its downstream-signaling pathways. Pharmacology 2007, 80:57-64.
17. Huang J.S., Chuang L.Y., Guh J.Y., Huang Y.J., Hsu M.S. Antioxidants attenuate high glucose-induced hypertrophic growth in renal tubular epithelial cells. Am J Physiol Renal Physiol 2007, 293:F1072-F1082.
18. Rowe L.A., Degtyareva N., Doetsch P.W. DNA damage-induced reactive oxygen species (ROS) stress response in Saccharomyces cerevisiae. Free Radic Biol Med 2008, 45:1167-1177.
19. Lambeth J.D. Nox enzymes. ROS, and chronic disease: an example of antagonistic pleiotropy. Free Radic Biol Med 2007, 43:332-347.
20. Verzola D., Bertolotto M.B., Villaggio B., Ottonello L., Dallegri F., Salvatore F., et al. Oxidative stress mediates apoptotic changes induced by hyperglycemia in human tubular kidney cells. J Am Soc Nephrol 2004, 15(Suppl. 1):S85-S87.
21. Gross A., Jockel J., Wei M.C., Korsmeyer S.J. Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J 1998, 17:3878-3885.
22. Green D.R., Reed J.C. Mitochondria and apoptosis. Science 1998, 281:1309-1312.
23. Li F., Chong Z.Z., Maiese K. Erythropoietin on a tightrope: balancing neuronal and vascular protection between intrinsic and extrinsic pathways. Neurosignals 2004, 13:265-289.
24. Joyeux-Faure M., Godin-Ribuot D., Ribuot C. Erythropoietin and myocardial protection: what's new?. Fundam Clin Pharmacol 2005, 19:439-446.
25. Fishbane S., Ragolia L., Palaia T., Johnson B., Elzein H., Maesaka J.K. Cytoprotection by darbepoetin/epoetin alfa in pig tubular and mouse mesangial cells. Kidney Int 2004, 65:452-458.
26. Okada A., Kinoshita Y., Maekawa T., Hassan M.S., Kawanami C., Asahara M., et al. Erythropoietin stimulates proliferation of rat-cultured gastric mucosal cells. Digestion 1996, 57:328-332.
27. Mioni R., Gottardello F., Bordon P., Montini G., Foresta C. Evidence for specific binding and stimulatory effects of recombinant human erythropoietin on isolated adult rat Leydig cells. Acta Endocrinol (Copenh) 1992, 127:459-465.
28. Masuda S., Nagao M., Takahata K., Konishi Y., Gallyas F., Tabira T., et al. Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. J Biol Chem 1993, 268:11208-11216.